StreetInsider.com News Articles http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 04 Mar 2026 06:36:33 -0500 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif StreetInsider.com News Articles http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday Ladenburg Thalmann Starts Inhibikase Therapeutics Inc (IKT) at Buy http://www.streetinsider.com/New+Coverage/Ladenburg+Thalmann+Starts+Inhibikase+Therapeutics+Inc+%28IKT%29+at+Buy/26106743.html <p>Ladenburg Thalmann analyst Aydin Huseynov initiates coverage on Inhibikase Therapeutics Inc (NASDAQ: IKT) with a Buy rating and a price target of $4.00.</p><p>For an analyst ratings summary and ratings history on Inhibikase Therapeutics Inc <a href="http://www.streetinsider.com/rating_history.php?q=IKT">click here</a>. For more ratings news on Inhibikase Therapeutics Inc <a href="http://www.streetinsider.com/stock_lookup_news.php?q=IKT&amp;type=analyst">click here</a>.</p><p>Shares of Inhibikase Therapeutics Inc closed at $1.91 yesterday.</p> http://www.streetinsider.com/New+Coverage/Ladenburg+Thalmann+Starts+Inhibikase+Therapeutics+Inc+%28IKT%29+at+Buy/26106743.html Wed, 04 Mar 2026 06:36:33 -0500 IKT Form 4 Inhibikase Therapeutics, For: Feb 21 Filed by: Cabell Christopher http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Inhibikase+Therapeutics%2C++For%3A+Feb+21++Filed+by%3A+Cabell+Christopher/26053884.html si-local-file:///var/storage/secattach/20260224/26053884.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Inhibikase+Therapeutics%2C++For%3A+Feb+21++Filed+by%3A+Cabell+Christopher/26053884.html Tue, 24 Feb 2026 20:54:00 -0500 IKT O.48149183 Form 4 Inhibikase Therapeutics, For: Feb 21 Filed by: Cabell Christopher http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Inhibikase+Therapeutics%2C++For%3A+Feb+21++Filed+by%3A+Cabell+Christopher/26053884.html si-local-file:///var/storage/secattach/20260224/26053884.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Inhibikase+Therapeutics%2C++For%3A+Feb+21++Filed+by%3A+Cabell+Christopher/26053884.html Tue, 24 Feb 2026 20:54:00 -0500 IKT O.48149183 Form 4 Inhibikase Therapeutics, For: Feb 21 Filed by: Aurentz Vincent http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Inhibikase+Therapeutics%2C++For%3A+Feb+21++Filed+by%3A+Aurentz+Vincent/26053889.html si-local-file:///var/storage/secattach/20260224/26053889.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Inhibikase+Therapeutics%2C++For%3A+Feb+21++Filed+by%3A+Aurentz+Vincent/26053889.html Tue, 24 Feb 2026 20:54:00 -0500 IKT O.48149183 Form 4 Inhibikase Therapeutics, For: Feb 21 Filed by: Aurentz Vincent http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Inhibikase+Therapeutics%2C++For%3A+Feb+21++Filed+by%3A+Aurentz+Vincent/26053889.html si-local-file:///var/storage/secattach/20260224/26053889.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Inhibikase+Therapeutics%2C++For%3A+Feb+21++Filed+by%3A+Aurentz+Vincent/26053889.html Tue, 24 Feb 2026 20:54:00 -0500 IKT O.48149183 Form 4 Inhibikase Therapeutics, For: Feb 21 Filed by: Munshi Amit http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Inhibikase+Therapeutics%2C++For%3A+Feb+21++Filed+by%3A+Munshi+Amit/26053872.html si-local-file:///var/storage/secattach/20260224/26053872.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Inhibikase+Therapeutics%2C++For%3A+Feb+21++Filed+by%3A+Munshi+Amit/26053872.html Tue, 24 Feb 2026 20:49:00 -0500 IKT O.48149183 Form 4 Inhibikase Therapeutics, For: Feb 21 Filed by: Munshi Amit http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Inhibikase+Therapeutics%2C++For%3A+Feb+21++Filed+by%3A+Munshi+Amit/26053872.html si-local-file:///var/storage/secattach/20260224/26053872.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Inhibikase+Therapeutics%2C++For%3A+Feb+21++Filed+by%3A+Munshi+Amit/26053872.html Tue, 24 Feb 2026 20:49:00 -0500 IKT O.48149183 Form SCHEDULE 13G/A Inhibikase Therapeutics, Filed by: ADAR1 Capital Management, LLC http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Inhibikase+Therapeutics%2C+++++++++++++++Filed+by%3A+ADAR1+Capital+Management%2C+LLC/26015712.html si-local-file:///var/storage/secattach/20260217/26015712.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Inhibikase+Therapeutics%2C+++++++++++++++Filed+by%3A+ADAR1+Capital+Management%2C+LLC/26015712.html Tue, 17 Feb 2026 18:22:00 -0500 IKT O.48149183 Form SCHEDULE 13G/A Inhibikase Therapeutics, Filed by: ADAR1 Capital Management, LLC http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Inhibikase+Therapeutics%2C+++++++++++++++Filed+by%3A+ADAR1+Capital+Management%2C+LLC/26015712.html si-local-file:///var/storage/secattach/20260217/26015712.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Inhibikase+Therapeutics%2C+++++++++++++++Filed+by%3A+ADAR1+Capital+Management%2C+LLC/26015712.html Tue, 17 Feb 2026 18:22:00 -0500 IKT O.48149183 Form SCHEDULE 13G/A Inhibikase Therapeutics, Filed by: Fairmount Funds Management LLC http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Inhibikase+Therapeutics%2C+++++++++++++++Filed+by%3A+Fairmount+Funds+Management+LLC/26013833.html si-local-file:///var/storage/secattach/20260217/26013833.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Inhibikase+Therapeutics%2C+++++++++++++++Filed+by%3A+Fairmount+Funds+Management+LLC/26013833.html Tue, 17 Feb 2026 16:32:00 -0500 IKT O.48149183 Form SCHEDULE 13G/A Inhibikase Therapeutics, Filed by: Fairmount Funds Management LLC http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Inhibikase+Therapeutics%2C+++++++++++++++Filed+by%3A+Fairmount+Funds+Management+LLC/26013833.html si-local-file:///var/storage/secattach/20260217/26013833.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Inhibikase+Therapeutics%2C+++++++++++++++Filed+by%3A+Fairmount+Funds+Management+LLC/26013833.html Tue, 17 Feb 2026 16:32:00 -0500 IKT O.48149183 Form SCHEDULE 13G/A Inhibikase Therapeutics, Filed by: PERCEPTIVE ADVISORS LLC http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Inhibikase+Therapeutics%2C+++++++++++++++Filed+by%3A+PERCEPTIVE+ADVISORS+LLC/26011996.html si-local-file:///var/storage/secattach/20260217/26011996.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Inhibikase+Therapeutics%2C+++++++++++++++Filed+by%3A+PERCEPTIVE+ADVISORS+LLC/26011996.html Tue, 17 Feb 2026 16:00:00 -0500 IKT O.48149183 Form SCHEDULE 13G/A Inhibikase Therapeutics, Filed by: PERCEPTIVE ADVISORS LLC http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Inhibikase+Therapeutics%2C+++++++++++++++Filed+by%3A+PERCEPTIVE+ADVISORS+LLC/26011996.html si-local-file:///var/storage/secattach/20260217/26011996.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Inhibikase+Therapeutics%2C+++++++++++++++Filed+by%3A+PERCEPTIVE+ADVISORS+LLC/26011996.html Tue, 17 Feb 2026 16:00:00 -0500 IKT O.48149183 Form SCHEDULE 13G/A Inhibikase Therapeutics, Filed by: Nantahala Capital Management, LLC http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Inhibikase+Therapeutics%2C+++++++++++++++Filed+by%3A+Nantahala+Capital+Management%2C+LLC/26001805.html si-local-file:///var/storage/secattach/20260213/26001805.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Inhibikase+Therapeutics%2C+++++++++++++++Filed+by%3A+Nantahala+Capital+Management%2C+LLC/26001805.html Fri, 13 Feb 2026 17:05:00 -0500 IKT O.48149183 Form SCHEDULE 13G/A Inhibikase Therapeutics, Filed by: Nantahala Capital Management, LLC http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Inhibikase+Therapeutics%2C+++++++++++++++Filed+by%3A+Nantahala+Capital+Management%2C+LLC/26001805.html si-local-file:///var/storage/secattach/20260213/26001805.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Inhibikase+Therapeutics%2C+++++++++++++++Filed+by%3A+Nantahala+Capital+Management%2C+LLC/26001805.html Fri, 13 Feb 2026 17:05:00 -0500 IKT O.48149183 Form SCHEDULE 13G/A Inhibikase Therapeutics, Filed by: Sands Capital Life Sciences Pulse Fund II, L.P. http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Inhibikase+Therapeutics%2C+++++++++++++++Filed+by%3A+Sands+Capital+Life+Sciences+Pulse+Fund+II%2C+L.P./25997545.html si-local-file:///var/storage/secattach/20260213/25997545.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Inhibikase+Therapeutics%2C+++++++++++++++Filed+by%3A+Sands+Capital+Life+Sciences+Pulse+Fund+II%2C+L.P./25997545.html Fri, 13 Feb 2026 11:31:00 -0500 IKT O.48149183 Form SCHEDULE 13G/A Inhibikase Therapeutics, Filed by: Sands Capital Life Sciences Pulse Fund II, L.P. http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Inhibikase+Therapeutics%2C+++++++++++++++Filed+by%3A+Sands+Capital+Life+Sciences+Pulse+Fund+II%2C+L.P./25997545.html si-local-file:///var/storage/secattach/20260213/25997545.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Inhibikase+Therapeutics%2C+++++++++++++++Filed+by%3A+Sands+Capital+Life+Sciences+Pulse+Fund+II%2C+L.P./25997545.html Fri, 13 Feb 2026 11:31:00 -0500 IKT O.48149183 BofA Securities Starts Inhibikase Therapeutics Inc (IKT) at Buy, PT $6 http://www.streetinsider.com/New+Coverage/BofA+Securities+Starts+Inhibikase+Therapeutics+Inc+%28IKT%29+at+Buy%2C+PT+%246/25870830.html <p>BofA Securities analyst Jason Zemansky initiates coverage on Inhibikase Therapeutics Inc (NASDAQ: IKT) with a Buy rating and a price target of $6.00.</p><p>The analyst comments "We initiate on Inhibikase with a Buy rating and a $6 PO. Inhibikase is a clinical-stage biotech advancing a prodrug (a drug metabolized to its active form by the body) of leukemia therapy imatinib for PAH. By reducing the TKI’s known GI side-effects, management believes it can harness the (thus far) encouraging—and possibly disease modifying—efficacy of the native drug. That said, investors seemed largely unfazed by FDA’s decision last Nov to forego a phase 2 http://www.streetinsider.com/New+Coverage/BofA+Securities+Starts+Inhibikase+Therapeutics+Inc+%28IKT%29+at+Buy%2C+PT+%246/25870830.html Wed, 21 Jan 2026 06:10:31 -0500 IKT BofA Securities Starts Inhibikase Therapeutics Inc (IKT) at Buy, PT $6 http://www.streetinsider.com/Analyst+Comments/BofA+Securities+Starts+Inhibikase+Therapeutics+Inc+%28IKT%29+at+Buy%2C+PT+%246/25870830.html <p>BofA Securities analyst Jason Zemansky initiates coverage on Inhibikase Therapeutics Inc (NASDAQ: IKT) with a Buy rating and a price target of $6.00.</p><p>The analyst comments "We initiate on Inhibikase with a Buy rating and a $6 PO. Inhibikase is a clinical-stage biotech advancing a prodrug (a drug metabolized to its active form by the body) of leukemia therapy imatinib for PAH. By reducing the TKI’s known GI side-effects, management believes it can harness the (thus far) encouraging—and possibly disease modifying—efficacy of the native drug. That said, investors seemed largely unfazed by FDA’s decision last Nov to forego a phase 2 http://www.streetinsider.com/Analyst+Comments/BofA+Securities+Starts+Inhibikase+Therapeutics+Inc+%28IKT%29+at+Buy%2C+PT+%246/25870830.html Wed, 21 Jan 2026 06:10:31 -0500 IKT BofA Securities Starts Inhibikase Therapeutics Inc (IKT) at Buy, PT $6 http://www.streetinsider.com/Hot+Comments/BofA+Securities+Starts+Inhibikase+Therapeutics+Inc+%28IKT%29+at+Buy%2C+PT+%246/25870830.html <p>BofA Securities analyst Jason Zemansky initiates coverage on Inhibikase Therapeutics Inc (NASDAQ: IKT) with a Buy rating and a price target of $6.00.</p><p>The analyst comments "We initiate on Inhibikase with a Buy rating and a $6 PO. Inhibikase is a clinical-stage biotech advancing a prodrug (a drug metabolized to its active form by the body) of leukemia therapy imatinib for PAH. By reducing the TKI’s known GI side-effects, management believes it can harness the (thus far) encouraging—and possibly disease modifying—efficacy of the native drug. That said, investors seemed largely unfazed by FDA’s decision last Nov to forego a phase 2 http://www.streetinsider.com/Hot+Comments/BofA+Securities+Starts+Inhibikase+Therapeutics+Inc+%28IKT%29+at+Buy%2C+PT+%246/25870830.html Wed, 21 Jan 2026 06:10:31 -0500 IKT BofA Securities Starts Inhibikase Therapeutics Inc (IKT) at Buy, PT $6 http://www.streetinsider.com/Hot+New+Coverage/BofA+Securities+Starts+Inhibikase+Therapeutics+Inc+%28IKT%29+at+Buy%2C+PT+%246/25870830.html <p>BofA Securities analyst Jason Zemansky initiates coverage on Inhibikase Therapeutics Inc (NASDAQ: IKT) with a Buy rating and a price target of $6.00.</p><p>The analyst comments "We initiate on Inhibikase with a Buy rating and a $6 PO. Inhibikase is a clinical-stage biotech advancing a prodrug (a drug metabolized to its active form by the body) of leukemia therapy imatinib for PAH. By reducing the TKI’s known GI side-effects, management believes it can harness the (thus far) encouraging—and possibly disease modifying—efficacy of the native drug. That said, investors seemed largely unfazed by FDA’s decision last Nov to forego a phase 2 http://www.streetinsider.com/Hot+New+Coverage/BofA+Securities+Starts+Inhibikase+Therapeutics+Inc+%28IKT%29+at+Buy%2C+PT+%246/25870830.html Wed, 21 Jan 2026 06:10:31 -0500 IKT Form 4 Inhibikase Therapeutics, For: Jan 05 Filed by: Iwicki Mark T http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Inhibikase+Therapeutics%2C++For%3A+Jan+05++Filed+by%3A+Iwicki+Mark+T/25820493.html si-local-file:///var/storage/secattach/20260107/25820493.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Inhibikase+Therapeutics%2C++For%3A+Jan+05++Filed+by%3A+Iwicki+Mark+T/25820493.html Wed, 07 Jan 2026 16:23:00 -0500 IKT O.48149183 Form 4 Inhibikase Therapeutics, For: Jan 05 Filed by: Iwicki Mark T http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Inhibikase+Therapeutics%2C++For%3A+Jan+05++Filed+by%3A+Iwicki+Mark+T/25820493.html si-local-file:///var/storage/secattach/20260107/25820493.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Inhibikase+Therapeutics%2C++For%3A+Jan+05++Filed+by%3A+Iwicki+Mark+T/25820493.html Wed, 07 Jan 2026 16:23:00 -0500 IKT O.48149183 Form 4 Inhibikase Therapeutics, For: Jan 05 Filed by: Cabell Christopher http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Inhibikase+Therapeutics%2C++For%3A+Jan+05++Filed+by%3A+Cabell+Christopher/25820480.html si-local-file:///var/storage/secattach/20260107/25820480.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Inhibikase+Therapeutics%2C++For%3A+Jan+05++Filed+by%3A+Cabell+Christopher/25820480.html Wed, 07 Jan 2026 16:22:00 -0500 IKT O.48149183 Form 4 Inhibikase Therapeutics, For: Jan 05 Filed by: Cabell Christopher http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Inhibikase+Therapeutics%2C++For%3A+Jan+05++Filed+by%3A+Cabell+Christopher/25820480.html si-local-file:///var/storage/secattach/20260107/25820480.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Inhibikase+Therapeutics%2C++For%3A+Jan+05++Filed+by%3A+Cabell+Christopher/25820480.html Wed, 07 Jan 2026 16:22:00 -0500 IKT O.48149183